Noralane M Lindor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/540472/publications.pdf

Version: 2024-02-01

74 papers

4,312 citations

30 h-index 63 g-index

74 all docs

74 docs citations

times ranked

74

8737 citing authors

#	Article	IF	CITATIONS
1	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. Gastroenterology, 2021, 160, 1164-1178.e6.	1.3	36
2	Penetrance and outcomes at 1-year following return of actionable variants identified by genome sequencing. Genetics in Medicine, 2021, 23, 1192-1201.	2.4	4
3	Increasing access to individualized medicine: a matched-cohort study examining Latino participant experiences of genomic screening. Genetics in Medicine, 2021, 23, 934-941.	2.4	6
4	Experiences of Latino Participants Receiving Neutral Genomic Screening Results: A Qualitative Study. Public Health Genomics, 2021, 24, 44-53.	1.0	3
5	Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1800-1808.	2.5	1
6	Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study. Npj Genomic Medicine, 2020, 5, 19.	3.8	7
7	Contribution of mRNA Splicing to Mismatch Repair Gene Sequence Variant Interpretation. Frontiers in Genetics, 2020, 11, 798.	2.3	19
8	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
9	Potential impact of family history–based screening guidelines on the detection of earlyâ€onset colorectal cancer. Cancer, 2020, 126, 3013-3020.	4.1	45
10	Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. Genetics in Medicine, 2019, 21, 71-80.	2.4	52
11	Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients. Journal of Immigrant and Minority Health, 2019, 21, 434-437.	1.6	13
12	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 28.	1.5	27
13	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 2019, 10, 2154.	12.8	172
14	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	1.5	42
15	Risks of Colorectal Cancer and Cancer-Related Mortality in Familial Colorectal Cancer Type X and Lynch Syndrome Families. Journal of the National Cancer Institute, 2019, 111, 675-683.	6.3	12
16	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
17	Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. American Journal of Human Genetics, 2018, 102, 233-248.	6.2	64
18	From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. Journal of Community Genetics, 2018, 9, 209-215.	1.2	5

#	Article	IF	CITATIONS
19	The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results. Mayo Clinic Proceedings, 2018, 93, 1600-1610.	3.0	29
20	Developing a Process for Returning Medically Actionable Genomic Variants to Latino Patients in a Federally Qualified Health Center. Public Health Genomics, 2018, 21, 77-84.	1.0	19
21	Leptin gene variants and colorectal cancer risk: Sex-specific associations. PLoS ONE, 2018, 13, e0206519.	2.5	17
22	Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. PLoS ONE, 2018, 13, e0196245.	2.5	9
23	Physical activity and the risk of colorectal cancer in Lynch syndrome. International Journal of Cancer, 2018, 143, 2250-2260.	5.1	23
24	DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome. Modern Pathology, 2018, 31, 1608-1618.	5.5	32
25	Whole-Genome Sequencing in Healthy People. Mayo Clinic Proceedings, 2017, 92, 159-172.	3.0	40
26	Non- BRCA familial breast cancer: review of reported pathology and molecular findings. Pathology, 2017, 49, 363-370.	0.6	32
27	Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. International Journal of Cancer, 2017, 140, 2701-2708.	5.1	76
28	Prediagnostic alcohol consumption and colorectal cancer survival: The Colon Cancer Family Registry. Cancer, 2017, 123, 1035-1043.	4.1	21
29	Longâ€ŧerm weight loss after colorectal cancer diagnosis is associated with lower survival: The Colon Cancer Family Registry. Cancer, 2017, 123, 4701-4708.	4.1	20
30	Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. European Journal of Cancer, 2017, 84, 228-238.	2.8	81
31	Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry. Molecular Genetics & Enomic Medicine, 2017, 5, 700-708.	1.2	1
32	Germline miRNA DNA variants and the risk of colorectal cancer by subtype. Genes Chromosomes and Cancer, 2017, 56, 177-184.	2.8	7
33	Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget, 2017, 8, 93450-93463.	1.8	23
34	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Journal of Oncology Practice, 2017, 13, 333-337.	2.5	29
35	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
36	Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. British Journal of Cancer, 2016, 115, 266-272.	6.4	57

#	Article	IF	CITATIONS
37	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. American Journal of Human Genetics, 2016, 98, 830-842.	6.2	201
38	Estimating cumulative risks for breast cancer for carriers of variants in uncommon genes. Familial Cancer, 2016, 15, 367-370.	1.9	4
39	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
40	Association of a let-7 miRNA binding region of <i>TGFBR1 </i> with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis, 2016, 37, 751-758.	2.8	16
41	CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. British Journal of Cancer, 2016, 114, 221-229.	6.4	18
42	Variation at 2q35 (<i>PNKD</i> and <i>TMBIM1</i>) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease. Human Molecular Genetics, 2016, 25, 2349-2359.	2.9	37
43	The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. New England Journal of Medicine, 2016, 374, 454-468.	27.0	227
44	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
45	Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic. Mayo Clinic Proceedings, 2016, 91, 297-307.	3.0	83
46	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	2.4	51
47	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
48	Genome-Wide Interaction Analyses between Genetic Variants and Alcohol Consumption and Smoking for Risk of Colorectal Cancer. PLoS Genetics, 2016, 12, e1006296.	3.5	38
49	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	3.3	35
50	Preferences regarding Return of Genomic Results to Relatives of Research Participants, Including after Participant Death: Empirical Results from a Cancer Biobank. Journal of Law, Medicine and Ethics, 2015, 43, 464-475.	0.9	28
51	Returning a Research Participant's Genomic Results to Relatives: Analysis and Recommendations. Journal of Law, Medicine and Ethics, 2015, 43, 440-463.	0.9	81
52	How well do whole exome sequencing results correlate with medical findings? A study of 89 Mayo Clinic Biobank samples. Frontiers in Genetics, 2015, 6, 244.	2.3	9
53	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
54	Mendelian Randomization Study of Body Mass Index and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1024-1031.	2.5	67

#	Article	IF	Citations
55	Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1229-1238.	2.5	44
56	A preliminary investigation of genetic counselors' information needs when receiving a variant of uncertain significance result: a mixed methods study. Genetics in Medicine, 2015, 17, 739-746.	2.4	24
57	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
58	A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. Scientific Reports, 2015, 5, 10442.	3.3	109
59	Association of Type and Location of <i>BRCA1 </i> and <i>BRCA2 </i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
60	Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants. JAMA - Journal of the American Medical Association, 2015, 313, 1133.	7.4	171
61	A genome-wide association study for colorectal cancer identifies a risk locus in 14q23.1. Human Genetics, 2015, 134, 1249-1262.	3.8	28
62	Response to ten Broeke and Nielsen. Genetics in Medicine, 2015, 17, 684-685.	2.4	0
63	Myhre-LAPs syndrome and intubation related airway stenosis: keys to diagnosis and critical therapeutic interventions. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2015, 36, 636-641.	1.3	12
64	Whole-Exome Sequencing of 10 Scientists: Evaluation of the Process and Outcomes. Mayo Clinic Proceedings, 2015, 90, 1327-1337.	3.0	10
65	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
66	Lynch Syndrome 101 (Years, That Is). American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 27-32.	3.8	2
67	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
68	Family History of Colorectal Cancer Is Not Associated with Colorectal Cancer Survival Regardless of Microsatellite Instability Status. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1700-1704.	2.5	9
69	Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. Human Molecular Genetics, 2014, 23, 4729-4737.	2.9	128
70	Colorectal cancer and self-reported tooth agenesis. Hereditary Cancer in Clinical Practice, 2014, 12, 7.	1.5	16
71	Genomic Medicine and Incidental Findings: Balancing Actionability and Patient Autonomy. Mayo Clinic Proceedings, 2014, 89, 718-721.	3.0	15
72	BRCA1/2 Sequence Variants of Uncertain Significance: A Primer for Providers to Assist in Discussions and in Medical Management. Oncologist, 2013, 18, 518-524.	3.7	76

#	Article	IF	CITATIONS
73	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1</i> /i>/ <i>2</i> (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
74	Central pontine myelinolysis as a complication of partial ornithine carbamoyl transferase deficiency. American Journal of Medical Genetics Part A, 1995, 60, 210-213.	2.4	20